EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy of Adjuvant Nivolumab versus Adjuvant Gemcitabine plus Cisplatin/Carboplatin after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Real-World Analysis Using a Japanese Large-Scale Claims Database

Akihito Hashizume, Takashi Kawahara, Masanobu Yamazaki, Daiki Ueno, Shinnosuke Kuroda, Teppei Takeshima, Daiji Takamoto, Takeaki Noguchi, Yasushi Yumura, Hiroji Uemura, Kazuhide Makiyama, Jun-ichi Teranishi

Urologia Internationalis · 2026-10-15 · 1-1

DOI: 10.1159/uin/aewag029 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy with a poor prognosis. Although adjuvant platinum-based chemotherapy is a standard treatment after radical nephroureterectomy (RNU), the efficacy of adjuvant nivolumab in UTUC remains unclear, especially in real clinical practice. We examined this using a large Japanese real-world database. Methods: Using the Medical Data Vision database, we identified UTUC patients who underwent RNU and received adjuvant therapy. The adjuvant GC/GCarbo group and the adjuvant nivolumab group were defined by distinct treatment eras to reduce treatment selection bias. Event-free survival (EFS) was compared using Kaplan-Meier curves and the log-rank test, with a sensitivity analysis truncating follow-up at 300 days. Results: A total of 1,058 patients were analyzed (240 nivolumab, 818 GC/GCarbo). In the whole cohort, EFS was significantly longer in the nivolumab group (HR = 0.6365, p = 0.0076). This association was consistent in patients with neoadjuvant chemotherapy (HR = 0.4053, p = 0.001) and in those without it (HR = 0.6765, p = 0.0462). Conclusion: In Japanese UTUC patients, adjuvant nivolumab was associated with a longer EFS than GC/GCarbo. Because this was an unadjusted, observational comparison, the finding should be interpreted with caution and regarded as hypothesis-generating.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →